Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Nov 2018
Multicenter StudyMale gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study.
After ileocaecal resection for Crohn's disease (CD), inflammatory lesions frequently recur on the anastomosis and/or on the neo-terminal ileum. ⋯ Male gender, active smoking at surgery and previous intestinal resection are associated with a higher risk of endoscopic post-operative recurrence, while post-operative anti-TNF treatment is associated with a lower risk.
-
Aliment. Pharmacol. Ther. · Nov 2018
Multicenter StudyPrevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
The real size of the gastro-oesophageal reflux disease (GERD) population not responding to proton pump inhibitor (PPI) therapy has still not been fully elucidated. Causes of PPI refractoriness include incorrect diagnosis and lack of adherence to therapy, in terms of incorrect dosage and timing. ⋯ True refractoriness in patients with GERD symptoms attending a secondary care setting is lower than previously reported. Following a careful history and optimal PPI dosing, the rate of refractoriness was 20%. True NERD constitutes only a third of the PPI-refractory group.
-
Aliment. Pharmacol. Ther. · Nov 2018
Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
Advanced fibrosis has been established as the most important predictor of overall mortality in patients with non-alcoholic fatty liver disease (NAFLD). In contrast to cirrhosis, advanced, non-cirrhotic NAFLD is difficult to identify and data from Germany are lacking. ⋯ The prevalence of metabolic comorbidities in a German population with non-cirrhotic biopsy-proven NAFLD is high. While the examined scores exhibit an acceptable specificity, liver stiffness measurement appeared to be superior to blood-based non-invasive surrogate scores in ruling out advanced fibrosis.
-
Aliment. Pharmacol. Ther. · Nov 2018
Retraction Of PublicationRetraction: Randomised clinical trial: The clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China by J. Sun, C. Yang, H. Zhao, P. Zheng, J. Wilkinson, B. Ng, Y. Yuan. Aliment Pharmacol Ther. 2015;42:845-854.
The above article from Alimentary Pharmacology & Therapeutics, published online on 31 July 2015 on Wiley Online Library (wileyonlinelibrary.com), and in Volume 42, pp. 845-854, has been retracted by agreement between the authors, J. Sun, C. Yang, H. ⋯ W. Howden, and John Wiley Sons Ltd. The retraction has been agreed upon following major protocol deviations at some study sites and several instances of non-compliance that are sufficiently serious to warrant the withdrawal of the Chinese New Drug Application for Gaviscon Double Action.